AXS26: Biosimilars Could Slash Specialty Drug Spend 20% by 2029

Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }McMahon GroupBy Gina ShawIf the pharmacy benefits industry achieves 80% ad